Boston Scientific Corporation vs Merck & Company, Inc. — Stock Comparison
Boston Scientific Corporation (BSX) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Boston Scientific Corporation narrowly edges Merck & Company, Inc. on Q·Score (6.6 vs 6 out of 10), led by Quality (7.4 vs 4.4) and Valuation (7.1 vs 7). Merck & Company, Inc. scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst consensus targets imply greater upside for BSX (+13.6%) than for MRK (+7.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Strong profitability with 17% net profit margins.
⚠ earnings contracting 22% year-over-year.
68% of 28 covering analysts have a positive rating.
⚠ weak profitability metrics drag quality score.
Analyst Consensus
Fundamentals
Frequently Asked Questions
BSX vs MRK: which stock scores better overall?
Based on Q·Score, Boston Scientific Corporation (BSX) scores 6.6/10 versus Merck & Company, Inc. (MRK) at 6/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BSX or MRK?
Merck & Company, Inc. (MRK) scores higher on Growth (5.1/10 vs 4.2/10). Boston Scientific Corporation reports revenue growth (1.4% YoY) while Merck & Company, Inc. reports (4.7% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BSX or MRK more attractively valued?
Boston Scientific Corporation (BSX) scores higher on Valuation (7.1/10 vs 7/10). BSX trades at 14.0× P/E versus MRK at 16.3×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BSX vs MRK?
There are 28 analysts covering BSX with a consensus price target of $50.03, and 26 analysts covering MRK with a consensus target of $159.91. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BSX or MRK?
Boston Scientific Corporation (BSX) scores higher on Quality (7.4/10 vs 4.4/10). Net profit margin: BSX at 16.6%, MRK at 3.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BSX or MRK?
Boston Scientific Corporation (BSX) scores higher on Financial Health (7/10 vs 7/10). Market beta: BSX at 0.58, MRK at 0.12. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BSX and MRK?
Boston Scientific Corporation (BSX) has a market capitalisation of $63.8B, while Merck & Company, Inc. (MRK) has a market cap of $366.4B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do BSX or MRK pay dividends?
BSX does not currently pay a dividend, while MRK pays a dividend yield of 2.27%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →